Summit Therapeutics (SMMT) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
United Therapeutics (UTHR) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 18.7% versus a loss of 26.4%. Over five years, SMMT leads with a +233.4% price change compared with +184.8% for UTHR. United Therapeutics is the larger company by market cap ($23.55 billion vs $14.03 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMMT | UTHR |
|---|---|---|
| Share price | $17.59 | $549.16 |
| Market cap | $14.03B | $23.55B |
| 1-day change | +2.45% | +3.07% |
| YTD return | -1.83% | +9.34% |
| 1-year return | -26.44% | +18.68% |
| 5-year return | +233.40% | +184.80% |
| P/E ratio (TTM) | — | 19.67 |
| Forward P/E | — | 16.25 |
| EPS (TTM) | $-1.11 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.18B |
| Revenue growth (YoY) | — | +10.61% |
| Net income (latest FY) | $-1.08B | $1.33B |
| Gross margin | — | 87.92% |
| Operating margin | — | 46.89% |
| Net margin | — | 41.94% |
| 52-week high | $29.23 | $609.35 |
| 52-week low | $12.07 | $409.07 |
| Distance from 52-week high | -39.82% | -9.88% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +69.13% | +18.30% |
| Average volume | 5.82M | 672.80K |
| Shares outstanding | 797.75M | 42.89M |
| Employees | 265 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed SMMT by 45.1 percentage points over the past year.
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
SMMT vs UTHR FAQ
Which is bigger, Summit Therapeutics or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $23.55B compared with $14.03B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, SMMT or UTHR?
UTHR returned +18.68% over the past 12 months, compared with -26.44% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Summit Therapeutics and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.